UK Markets closed

Onxeo SA (0NWK.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.4270+0.4270 (+75.09%)
At close: 05:43PM GMT
Full screen
Previous close0.0000
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.0000 - 0.0000
52-week range
Volume579,530
Avg. volumeN/A
Market cap24.127M
Beta (5Y monthly)1.33
PE ratio (TTM)42.70
EPS (TTM)0.0100
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Onxeo Announces its Financial Agenda for 2023

    PARIS, January 27, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced its financial agenda for 2023.

  • Business Wire

    ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM

    PARIS, January 25, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM.

  • Business Wire

    Onxeo: Extraordinary General Meeting of February 6, 2023: Availability of Preparatory Documents

    PARIS, January 18, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, today announces the availability of the preparatory documents for its Extraordinary General Meeting which will be held on Monday, February 6, 2023 at 2:00 p.m. at the Renaissance Paris Nobel Tour Eif